-+ 0.00%
-+ 0.00%
-+ 0.00%

ENDRA Life Sciences Activates TAEUS System To Initiate Clinical Study At LMU University Hospital In Germany; Scans First Patient In Post-CE Mark Clinical Study With Munich's Center Of Excellence In Europe's Largest Healthcare Market

Benzinga·10/22/2024 12:14:21
Listen to the news

Scans first patient in post-CE mark clinical study with Munich's center of excellence in Europe's largest healthcare market

ENDRA Life Sciences Inc.(NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe.

LMU University Hospital is conducting a post market clinical study to collect data to assess TAEUS' liver fat measurement capabilities against the gold standard MRI-PDFF test. This study is intended to collect real-world clinical evidence to further establish the utility of the TAEUS system for metabolic disease management. LMU researchers plan to present the findings of the study at future medical congresses followed by a peer-reviewed publication.